+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 32 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602706
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Undisclosed and Women's Health which include indications Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Infantile Spasm (West Syndrome), Lennox-Gastaut Syndrome, Melanoma, Parkinson's Disease, Post Partum Depression (Maternal Depression / Postnatal Depression), Schizophrenia, Status Epilepticus and Unspecified.

The latest report Metabotropic Glutamate Receptor 1 - Drugs In Development, 2022, outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
  • The report reviews Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Overview
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Companies Involved in Therapeutics Development
ALS Biopharma LLC
Bio-Pharm Solutions Co Ltd
Nobias Therapeutics Inc
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Drug Profiles
FC-3423 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NB-001 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize mGlu1 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize mGluR1 for Depression - Drug Profile
Product Description
Mechanism Of Action
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Dormant Products
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Discontinued Products
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Product Development Milestones
Featured News
Dec 08, 2021: A potential new approach for the treatment of schizophrenia
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development by Stage of Development, 2022
  • Number of - Products under Development by Therapy Areas, 2022
  • Number of - Products under Development by Indication, 2022
  • Number of - Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by ALS Biopharma LLC, 2022
  • Pipeline by Bio-Pharm Solutions Co Ltd, 2022
  • Pipeline by Nobias Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022
List of Figures
  • Number of - Products under Development by Stage of Development, 2022
  • Number of - Products under Development by Therapy Areas, 2022
  • Number of - Products under Development by Top 10 Indications, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ALS Biopharma LLC
  • Bio-Pharm Solutions Co Ltd
  • Nobias Therapeutics Inc